The recently announced results of the NCT02484404 Phase 1/2 trial presented a surprising outcome. The triple combination therapy of Durvalumab (Imfinzi), Olaparib (Lynparza), and Cediranib, tested in patients with recurrent ovarian cancer, failed to meet the primary endpoint of objective response rate (ORR). In contrast, the Durvalumab and Cediranib combination achieved an ORR of 29.6%, demonstrating the primary endpoint. This suggests that the synergistic effect of these two mechanisms, which modulate the tumor microenvironment, may be more effective than the complexity of a triple therapy.

Cediranib, a VEGFR inhibitor, works by blocking blood supply to the tumor and inducing temporary hypoxia. Combining this with Durvalumab, which targets PD-L1, is expected to enhance immune cell infiltration into the tumor, maximizing the anti-cancer effect. The 29.6% response rate observed in the combination group is a very promising result compared to existing single-agent therapies, demonstrating the significant anti-cancer efficacy of the combination. However, the triple combination, which also includes Olaparib, a PARP inhibitor that blocks DNA damage repair, only achieved a 19.4% response rate.

The lower response rate observed in the triple therapy compared to the doublet therapy is likely due to complex drug toxicity and cumulative side effects. Patients in the triple therapy group may have experienced decreased adherence to the treatment regimen or required dose reductions due to adverse events. In clinical trials, drug toxicity can often lead to failure to administer the planned dose on time, resulting in reduced efficacy. This trial highlights that indiscriminate multi-target combination therapy is not always effective in cancer treatment, and that appropriate toxicity management and optimized doublet combinations may be more effective.

Currently, platinum-based chemotherapy is the standard treatment for recurrent ovarian cancer, often combined with anti-angiogenic agents such as Bevacizumab (Avastin). In the competitive landscape, GSK's PARP inhibitor Zejula (Niraparib) is widely used as a single-agent maintenance therapy, and ImmunoGen's targeted ADC therapy Elahere (Mirvetuximab soravtansine) is emerging as a new alternative. In this competitive environment, AstraZeneca has gained a new option with the Durvalumab and Cediranib combination, which can target patients with platinum-resistant tumors.

The global ovarian cancer treatment market is estimated at $3.8 billion in 2025 and is expected to grow to $5.8 billion, with an annual growth rate of 4% to 9%, exceeding $10 billion by the mid-2030s. AstraZeneca has already established a strong presence in this market with Lynparza, but it urgently needs to secure sustainable growth drivers due to regulatory agencies' efforts to reduce the indications for PARP inhibitors. Although the triple combination failed, the identification of the Durvalumab and Cediranib combination as an alternative means that AstraZeneca will continue to maintain its ovarian cancer portfolio and strengthen its competitiveness.